Overview

Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
In 2005-2006, a clinical trial was carried out to test safety, tolerability and efficacy of the combination chlorproguanil-dapsone+artesunate (CD+A): 800 children aged 12-59 months with uncomplicated P. falciparum malaria randomly allocated to AQ+SP or CD+A were followed up until day 28 after treatment. Adverse events, clinical and parasitological outcomes were recorded.
Phase:
N/A
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborator:
Institute of Tropical Medicine, Belgium
Treatments:
Artemisinins
Artesunate
Chlorproguanil
Dapsone
Proguanil